Mycobacterium Abscessus Complex Representatives in Patients With Bronchopulmonary Pathology: Prevalence, Peculiarities of Cultivation and Identification

Abstract

More and more publications appear in the modern literature on the increase in the prevalence of non-tuberculous mycobacteria (NTMs), in particular, representatives of M. chelonae / Mycobacterium abscessus complex (MABSc). The paper presents data on the current classification of M. chelonae / Mycobacterium abscessus complex and its main representatives. The main data on the possible sources and ways of infection of MABSc patients in hospital are presented. The main features of cultivation on various nutrient media and their possible identification using modern methods are also indicated. The main risk factors for the development of mycobacteriosis in patients and the possible clinical picture are described. The prevalence of MABSc representatives in the structure of non-tuberculous mycobacteria isolated from clinical material from 483 patients from the Samara region was assessed for examination for tuberculosis, and the prevalence from 933 patients with cystic fibrosis (CF) from 55 regions of the Russian Federation from 2016 to 2019 was estimated. In total, as a result of the study, 316 NTM strains (65.4%) were isolated and identified in the first group of patients. M.abscessus was isolated and identified 10 strains and 5 strains - M.chelonae, which amounted to 3.2% and 1.6%, respectively, of all NTMs. In general, MABSc representatives were isolated in 3.1% of the examined patients. As a result of a screening study of patients with CF, 14194 microorganism strains from 933 patients were isolated and identified. Altogether M. abscessus was isolated and confirmed from 14 patients of different ages. Thus, the prevalence of MABSc among the examined patients with CF in the Russian Federation was 1.5%.

An Artefactual Cluster of Mycobacterium abscessus Pneumonia among Cancer Patients Arising from Contamination

“…Multicentre studies have reported prevalence ranging from 2.7% in Europe to 14% in the United States, where MABC infections are the second most common mycobacterial infections after M. avium infections [12,[16][17][18]. In the Russian Federation, MABC species were isolated from 3.1% of examined patients and the prevalence among patients with cystic fibrosis was 1.5% [19]. In Taiwan, members of the MABC comprise 17.2% of all clinical NTM isolates, equivalent to 1.7 cases per 100,000 population [20].…”